Our Proseek® results are in agreement with previous studies [58, 59], as we found that HE4 consistently performed very closely to CA125, with AUC values of 0.85–1.0 when comparing sera from early and late stage serous ovarian cancer patients to sera from healthy women or women with benign ovarian disease. This evidence concerns the gene MUC16 and ovarian serous adenocarcinoma.